Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and more than a third after undergoing radiation therapy. Men with metastatic prostate cancer have particularly poor prognoses, with a five-year survival rate of only 30% to 50%. In short, it is difficult to predict which treatment, or combination of treatments, will lead to longer survival for this group of men with aggressive (metastatic) prostate cancer. In the laboratory, it is possible to grow small samples of tumors into 3D mini-tumors. These mini-tumors retain the characteristics of the patient's original tumor tissue. Various treatments can be tested on these 3D mini-tumors to determine which therapy is most effective for each individual case. There are currently two techniques available for creating these 3D mini-tumors in the lab. In this project, we aim to investigate which of these two techniques works best in order to test and personalize treatments.

NCT Number	NCT07004582
Lead Sponsor	Maastricht Radiation Oncology Collaborators: Zuyderland Medical Centre, Maastricht University Medical Center
Conditions	Prostate Cancer, Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Advanced Prostate Cancer
Enrollment	600 participants
Start Date	2026-03-15
Primary Completion	2031-09-30 (estimated)
Study Completion	2031-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-23